{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:41:31Z","timestamp":1790275291229,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"French Health Ministry","award":["PHRC09_24-007"],"award-info":[{"award-number":["PHRC09_24-007"]}]},{"name":"SIRIC","award":["INCa-DGOS-INSERM 6038"],"award-info":[{"award-number":["INCa-DGOS-INSERM 6038"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.08.025","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T15:37:59Z","timestamp":1506181079000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Mathilde","family":"Guerin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Isambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Autret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Pakradouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Provansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Camerlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Charafe-Jauffret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Extra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Viens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lokiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Boher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4785","key":"10.1016\/j.ejca.2017.08.025_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejca.2017.08.025_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ejca.2017.08.025_bib3","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2017.08.025_bib4","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2017.08.025_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2017.08.025_bib6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2017.08.025_bib7","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2017.08.025_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic Identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ejca.2017.08.025_bib9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.08.025_bib10","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-11-2750","article-title":"Dual mTORC1\/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy","volume":"18","author":"Garc\u00eda-Garc\u00eda","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2017.08.025_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-010-1232-1","article-title":"The PI3 kinase\/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells","volume":"129","author":"Br\u00fcnner-Kubath","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ejca.2017.08.025_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","article-title":"Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor","volume":"11","author":"Maira","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ejca.2017.08.025_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2017.08.025_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2017.08.025_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-13-1070","article-title":"Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy","volume":"20","author":"Saura","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2017.08.025_bib16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/1078-0432.CCR-15-1745","article-title":"A phase I trial of BKM120 (buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2017.08.025_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O'Brien","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ejca.2017.08.025_bib18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2014.04.031","volume":"50","author":"Postel-Vinay","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2017.08.025_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.08.025_bib20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2017.08.025_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.08.025_bib22","doi-asserted-by":"crossref","first-page":"e39626","DOI":"10.1371\/journal.pone.0039626","article-title":"Multiorgan metastasis of human HER-2+ breast cancer in Rag2-\/-; Il2rg-\/- mice and treatment with PI3K inhibitor","volume":"7","author":"Nanni","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ejca.2017.08.025_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2017.08.025_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4120","article-title":"Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases","author":"Ni","year":"2016","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.ejca.2017.08.025_bib25","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2015.63.9161","article-title":"Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3","volume":"34","author":"Andr\u00e9","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4 Suppl.","key":"10.1016\/j.ejca.2017.08.025_bib26","article-title":"Abstract S4-07: BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2\u2013, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment","volume":"77","author":"Leo","year":"2017","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2017.08.025_bib27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.08.025_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2017.08.025_bib29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T05:21:02Z","timestamp":1535347262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917312509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":29,"alternative-id":["S0959804917312509"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}